Sign in Subscribe
Cancer research

Promising Vaccine Results for Pancreatic and Colorectal Cancer Patients

Strategic Insights

— 1 min read

A phase 1 study published in Nature Medicine has shown encouraging results for a vaccine designed to treat patients with pancreatic and colorectal cancer. The vaccine, ELI-002 2P, has been found to generate strong T cell responses in 68% of patients, which correlated with longer recurrence-free and overall survival. However, the study's authors caution that the results are preliminary and require further validation in larger trials.

Key Takeaways:

  • The phase 1 study, conducted on 25 patients with pancreatic and colorectal cancer, evaluated the safety and immunogenicity of the ELI-002 2P vaccine.
  • The vaccine elicited strong mKRAS-specific T cell responses in 68% of patients, which correlated with improved relapse-free and overall survival.
  • The study's authors noted that the results are promising but require further validation in larger, randomized trials.
  • The vaccine targets mutant KRAS proteins, which are present in approximately 95% of pancreatic cancer cases and 50% of colorectal cancer cases.
  • The study's results are encouraging for the development of novel treatments for patients with minimal residual disease (MRD) in pancreatic and colorectal cancer.

Statistics:

  • 68% of patients in the study had strong mKRAS-specific T cell responses, which correlated with improved relapse-free and overall survival.
  • The study involved 25 patients, with 20 having pancreatic cancer and 5 having colorectal cancer.
  • The patients had minimal residual disease (MRD) following standard treatment, and the study evaluated the ELI-002 2P vaccine's ability to target mutant KRAS proteins.
  • The vaccine generated polyfunctional CD4+ and CD8+ T cell immunity to mKRAS, which is a significant step forward in cancer immunoprevention and vaccine-based therapy.

Sources:

  • "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results" by Zev A. Wainberg et al., published in Nature Medicine, DOI: https://doi.org/10.1038/s41591-025-03876-4
  • Quotes from Dr. Magnus Dillon, Dr. Khurum Khan, and Prof. Richard Sullivan.

Read more